Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
administered by aerosolization in patients with non-small-cell lung cancer (any stage.
To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days
per week X 8 weeks, every 10 weeks.
To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A
specific protocol will be written for this part.